Literature DB >> 20452142

Outcomes of WHO Grade I meningiomas receiving definitive or postoperative radiotherapy.

Emily Tanzler1, Christopher G Morris, Jessica M Kirwan, Robert J Amdur, William M Mendenhall.   

Abstract

PURPOSE: We analyzed long-term local control and complications in patients with either pathologically confirmed or clinical World Health Organization Grade I meningiomas treated with definitive or postoperative radiotherapy (RT) at the University of Florida.
METHODS: Between 1984 and 2006, 146 patients were treated with definitive (n = 88) or postoperative RT after subtotal resection (n = 57) or gross total resection (n = 1). Patients were treated with conventional (n = 41), stereotactic (n = 103), or intensity-modulated RT (n = 2) to a median dose of 52.7 Gy and followed for a median of 7.3 years (range, 0.6-22.0 years)
RESULTS: The local control rates at 5 and 10 years were as follows: definitive RT, 99% and 99%; postoperative RT, 96% and 93%; and overall, 97% and 96%, respectively. The 5- and 10-year cause-specific survival rates were as follows: definitive RT 94% and 94%, postoperative RT, 100% and 96%; and overall, 96% and 95%, respectively. The 5- and 10-year overall survival rates were as follows: definitive RT, 81% and 75%; postoperative RT, 96% and 85%; and overall, 87% and 79%, respectively. Severe RT complications occurred in 6.8% of patients; severe surgery-related complications occurred in 10 (17%) of 58 patients treated surgically.
CONCLUSIONS: The likelihood of cure after definitive RT or following subtotal resection is excellent. However, a small population of patients experience severe complications, even at the moderate dose used for this disease. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20452142     DOI: 10.1016/j.ijrobp.2009.11.032

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Reference gene selection for real-time quantitative PCR analysis on ovarian cryopreservation by vitrification in mice.

Authors:  Shan Yuanyuan; Su Qin; Xu Rongrong; Gao Yujing; Pei Chengbin; Ma Jianjun; Yang Yanzhou; Pei Xiuying
Journal:  J Assist Reprod Genet       Date:  2015-06-27       Impact factor: 3.412

Review 2.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

3.  Prospective, Randomized Study of Radiation Dose Escalation With Combined Proton-Photon Therapy for Benign Meningiomas.

Authors:  Nina N Sanford; Beow Y Yeap; Mykol Larvie; Juliane Daartz; John E Munzenrider; Norbert J Liebsch; Barbara Fullerton; Elizabeth Pan; Jay S Loeffler; Helen A Shih
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-07-12       Impact factor: 7.038

4.  Review of photon and proton radiotherapy for skull base tumours.

Authors:  Piero Fossati; Andrea Vavassori; Letizia Deantonio; Eleonora Ferrara; Marco Krengli; Roberto Orecchia
Journal:  Rep Pract Oncol Radiother       Date:  2016-04-16

5.  Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography.

Authors:  Mats Ryttlefors; Torsten Danfors; Francesco Latini; Anders Montelius; Erik Blomquist; Olafur Gudjonsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-28       Impact factor: 9.236

6.  Short diameter may be a useful simple indicator of the tumor response in skull base meningiomas after conventionally fractionated stereotactic radiotherapy.

Authors:  Keiichi Takehana; Daisuke Nakamura; Alshaymaa Abdelghaffar; Megumi Uto; Tomohiro Katagiri; Yoshiki Arakawa; Yohei Mineharu; Susumu Miyamoto; Takashi Mizowaki
Journal:  Eur Radiol       Date:  2021-02-10       Impact factor: 5.315

7.  Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas.

Authors:  Giuseppe Minniti; Enrico Clarke; Luigi Cavallo; Mattia Falchetto Osti; Vincenzo Esposito; Gianpaolo Cantore; Paolo Cappabianca; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2011-04-12       Impact factor: 3.481

8.  Ki67 Index Is the Most Powerful Factor for Predicting the Recurrence in Atypical Meningioma : Retrospective Analysis of 99 Patients in Two Institutes.

Authors:  Sang Hyuk Lee; Eun Hee Lee; Kyoung Su Sung; Dae Cheol Kim; Young Zoon Kim; Young Jin Song
Journal:  J Korean Neurosurg Soc       Date:  2022-04-14

Review 9.  Advances in Multidisciplinary Management of Skull Base Meningiomas.

Authors:  Tamara Ius; Alessandro Tel; Giuseppe Minniti; Teresa Somma; Domenico Solari; Michele Longhi; Pasquale De Bonis; Alba Scerrati; Mario Caccese; Valeria Barresi; Alba Fiorentino; Leonardo Gorgoglione; Giuseppe Lombardi; Massimo Robiony
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

10.  Epigenetic Role of Histone 3 Lysine Methyltransferase and Demethylase in Regulating Apoptosis Predicting the Recurrence of Atypical Meningioma.

Authors:  Sang Hyuk Lee; Eun Hee Lee; Sung-Hun Lee; Young Min Lee; Hyung Dong Kim; Young Zoon Kim
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.